Loading clinical trials...
Loading clinical trials...
A Phase II Study of the Addition of Opaganib to Androgen Antagonists in Patients With Prostate Cancer Progression on Enzalutamide or Abiraterone
Conditions
Interventions
Opaganib
Abiraterone
+2 more
Locations
2
United States
Emory University
Atlanta, Georgia, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Start Date
March 27, 2020
Primary Completion Date
August 31, 2023
Completion Date
July 31, 2024
Last Updated
September 25, 2024
NCT06594926
NCT06257264
NCT03620786
NCT05939414
NCT05424783
NCT04693377
Lead Sponsor
Medical University of South Carolina
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions